From: Systemic and central nervous system metabolic alterations in Alzheimer’s disease
Clinical characteristics | AD (n = 40) | Control (n = 34) | P valuea |
---|---|---|---|
Female, n (%) | 24 (60.00) | 23 (67.65) | 0.6098 |
BMI, kg/m2, mean ± SD | 23.83 ± 3.06 | 24.60 ± 4.01 | 0.3637 |
Age, year, mean ± SD | 74.88 ± 6.38 | 65.35 ± 6.17 | < 0.0001 |
Cognitive function | |||
MMSE, mean ± SD | 24.40 ± 4.15 | 28.71 ± 1.29 | < 0.0001 |
CDR, mean ± SD | 0.65 ± 0.30 | 0.00 ± 0.00 | < 0.0001 |
AD CSF biomarkers | |||
Aβ1–42, pg/ml, mean ± SD | 556.22 ± 115.39 | 979.12 ± 164.38 | < 0.0001 |
Tau, pg/ml, mean ± SD | 715.70 ± 300.05 | 196.18 ± 59.72 | < 0.0001 |
pTau-181, pg/ml, mean ± SD | 91.95 ± 23.84 | 42.91 ± 10.51 | < 0.0001 |
Biochemical measures | |||
ApoEε4, n (%ε4) | 26 (65.00) | 6 (17.64) | < 0.0001 |
Qalb, mean ± SD | 6.69 ± 3.76 | 5.27 ± 1.82 | 0.0474 |